|Genotypic Technology in association with Invitrogen Bioservices India Ltd
Organizes a workshop on
Next Generation Sequencing in Clinics: Detection of Mutation spectrum of important cancer-related genes from clinical samples
Date:5th and 6th October 2012
Venue: Genotypic Technology Pvt Ltd, Bengaluru
Hurry!! Limited registrations only!!......
Download brochure | Email us: genomicsatgenotypic.co.in | Click to register
Discover and identify cancer marker genes involved in gene regulation, tumor suppression and oncogenesis using Ion AmpliSeqTM at Genotypic, the India’s first Ion Torrent Certified Service Provider
Analyze multiple cancer markers in single reaction to identify cancers including Pancreatic, Gastric, Colorectal, Breast, Lung, Blood, Liver, Prostate, Skin, Ovarian,
Thyroid and many more
We encourage participants to get any tumor samples (DNA, FFPE tissues, DNA from FFPE tissues, cultured cells, fine needle aspirates) for hands on Next Generation Sequencing experience
Who Should Attend?
Clinical oncologists, cancer researchers, clinicians, pathologists, lab managers, lab technicians ...
Workshop allows you to discuss with experts the power of Next generation sequencing using Ion AmpliSeqTM, customization, data interpretation, use of softwares and many more.
|Genotypic Offerings to Cancer Genomics Research: Completed
over 100 projects on Cancer and drug discovery using
Microarrays and Next Generation Sequencing
Other services by Genotypic
- Perform CGH arrays (Normal Vs Tumor) and discover chromosomal aberrations (InDels)
- Identify transcriptional signature genes by gene expression and miRNA profiling
- Perform Next Generation sequencing to scan whole genome, transcriptome and epigenome in short span of time
- Combine power of Next Generation Sequencing with Microarrays to get greater insight into functional Cancer genomics.
Click on title to download workshop presentation and name to view speaker profile
"T.S. Sridhar is currently at the St. John's Research Institute, working on establishing a comprehensive atlas of molecular alterations and clinical outcomes in breast cancer in Indian women. He was previously head of Triesta Sciences as well as ReaMetrix India operations. He has an MBBS from KMC Manipal, PhD from CCMB Hyderabad and did his neurology residency training at Wash. U., St. Louis, and fellowship at Harvard Medical School."
An albums of IISc., (1951-57), Tufts New England Medical Centre, and visiting faculty to Correll University Medical College, Karotinska Institute (Medical Genetics) is a Biomedical Scientist, with over 40 years’ experience, in clinical Laboratory Medicine, and Institution building, in health care, Research and training.
Author of over 100 publications in diverse biological areas, including clinical chemistry, enzymology, basic human nutrition and diabetes, post translational modification of proteins, amino acid malnutrition, are some of his special interests. Was a International Cancer Union. Fellow and an elected fellow of Indian college of Cardiology (one of the few non-clinical fellows) for his contributions to basic understanding of the complications of diabetes, leading to CVD. Currently, engaged in an advisory capacity to several health care and teaching institutions in Medicine in the field of translational research particularly relating to molecular genetics.
Dr. Anand Damodaran is a medical doctor specializing in Pathology and also a genomics scientist with 14 years of overall research experience after his MBBS which he obtained from Madras Medical College, Chennai in 1998. Following several research internships at leading labs in India he moved to the USA in 2000 to complete a postdoctoral research fellowship in immunogenetics of bone marrow transplantation at the prestigious Fred Hutchinson Cancer Research Center, Seattle, Washington. During his ~seven year research at Seattle, Dr. Anand has worked directly in the lab and clinic on the genetic basis of Graft verus Host Disease in transplant patients through discovery and validation of several new genomic markers in addition to HLA genes through the use of molecular and immunological methods. He optimized the assay for Whole Genome SNP microarrays for the discovery of novel markers and screened for markers in transplant patients.
In 2007, he joined Genotypic Technology as Research Director and taken several successful R &D initiatives, writing proposals and grants, running internal and external R &D projects involving applications of microarrays and Next Generation DNA Sequencing. He was also managing international collaborations and involved in scientific planning of projects with clients especially related to the clinics. He was directly involved in a Indo-US NIH research grant that was approved. He actively represented Genotypic on several scientific forums in India and abroad.
In 2011, Dr. Anand joined SRM Medical College, SRM University in Chennai to specialize in Pathology and also as a research advisor. He has got several publications, book chapters to his credit and some manuscripts submitted and in preparation. His career emphasis is on Molecular Pathology and Translational research- to take the fruits from the lab to the clinic, especially to India.